Mirum Pharma SVP sells 658 shares at $100

Q: At what price were the Mirum Pharmaceuticals (MIRM) shares sold in this Form 4 filing?

The filing states that the 658 shares of Mirum Pharmaceuticals common stock were sold at a price of $100.00 per share. The sale is described as having occurred in an open market or private transaction on September 2, 2026.

Mirum Pharmaceuticals’ SVP and Global Controller reported a pre-arranged sale of 658 common shares under a Rule 10b5-1 trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) reported that Jolanda Howe, its Senior Vice President and Global Controller, sold 658 shares of common stock on September 2, 2026 in a sale described as occurring in the open market or a private transaction at $100.00 per share.

After this sale, Howe held 616 shares of Mirum common stock directly. The transaction was carried out pursuant to a Rule 10b5-1 trading plan adopted by Howe on March 18, 2026, indicating it was pre-arranged.

Insider Trade Summary 10b5-1

Net Seller: 658 shares

Net Sell 1 txn

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Sold 658 shs ($66K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	658	$100.00	$66K

Holdings After Transaction: Common Stock — 616 shares (Direct)

Footnotes (1)

F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

Key Figures

Shares sold: 658 shares Sale price per share: $100.00 per share Shares held after transaction: 616 shares +1 more

4 metrics

Shares sold 658 shares Common stock sale reported for September 2, 2026

Sale price per share $100.00 per share Price for the 658 shares of common stock sold

Shares held after transaction 616 shares Direct holdings of Jolanda Howe following the sale

Rule 10b5-1 plan adoption date March 18, 2026 Date Howe adopted the trading plan used for this sale

Key Terms

Rule 10b5-1 Plan, open market or private transaction, Common Stock

3 terms

Rule 10b5-1 Plan regulatory

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction market

"Sale in open market or private transaction"

Common Stock financial

"Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

What insider transaction did Mirum Pharmaceuticals (MIRM) disclose for Jolanda Howe?

Mirum disclosed that Senior Vice President and Global Controller Jolanda Howe sold 658 shares of common stock on September 2, 2026 in a transaction described as an open market or private sale at $100.00 per share, under a pre-arranged trading plan.

How many Mirum Pharmaceuticals (MIRM) shares does Jolanda Howe hold after the reported sale?

After the reported transaction, Jolanda Howe directly holds 616 shares of Mirum Pharmaceuticals common stock. This figure reflects her position immediately following the 658-share sale reported for September 2, 2026.

At what price were the Mirum Pharmaceuticals (MIRM) shares sold in this Form 4 filing?

The filing states that the 658 shares of Mirum Pharmaceuticals common stock were sold at a price of $100.00 per share. The sale is described as having occurred in an open market or private transaction on September 2, 2026.

Was the insider sale of Mirum Pharmaceuticals (MIRM) stock made under a Rule 10b5-1 plan?

Yes. A footnote explains that the reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by Jolanda Howe on March 18, 2026, indicating the sale was pre-arranged under that trading plan.

What is the role of Jolanda Howe at Mirum Pharmaceuticals (MIRM) mentioned in the Form 4?

The Form 4 identifies Jolanda Howe as an officer of Mirum Pharmaceuticals serving as Senior Vice President, Global Controller. The reported transaction relates to her holdings of the company’s common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 06:55 PM Accepted by SEC EDGAR 09/03/2026 - 06:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, GLOBAL CONTROLLER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/02/2026		S⁽¹⁾		658	D	$100	616	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 18, 2026.

	/s/ Judit Ryvkin, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR